Free Trial
NASDAQ:ADVM

Adverum Biotechnologies Q3 2024 Earnings Report

Adverum Biotechnologies logo
$2.93 -0.05 (-1.68%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$2.94 +0.00 (+0.17%)
As of 04/17/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adverum Biotechnologies EPS Results

Actual EPS
-$1.30
Consensus EPS
-$1.20
Beat/Miss
Missed by -$0.10
One Year Ago EPS
N/A

Adverum Biotechnologies Revenue Results

Actual Revenue
$1.00 million
Expected Revenue
$0.50 million
Beat/Miss
Beat by +$500.00 thousand
YoY Revenue Growth
N/A

Adverum Biotechnologies Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Monday, November 4, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Adverum Biotechnologies' next earnings date is estimated for Thursday, May 8, 2025, based on past reporting schedules.

Adverum Biotechnologies Earnings Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
My friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92% win rate trading system is built to profit in any market – whether Bitcoin is mooning, correcting, or chopping sideways. No more guessing. No more stress. Just precision trades that put you in control.
RBC Capital Keeps Their Hold Rating on Adverum Biotechnologies (ADVM)
Adverum Biotechnologies sees cash runway into 2H25
TD Cowen Reaffirms Their Buy Rating on Adverum Biotechnologies (ADVM)
See More Adverum Biotechnologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adverum Biotechnologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adverum Biotechnologies and other key companies, straight to your email.

About Adverum Biotechnologies

Adverum Biotechnologies (NASDAQ:ADVM), a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

View Adverum Biotechnologies Profile

More Earnings Resources from MarketBeat